207 related articles for article (PubMed ID: 36459496)
1. A subset of VEGFR-TKIs activates AMPK in LKB1-mutant lung cancer.
Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
4. Carnosic Acid against Lung Cancer: Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling.
O'Neill EJ; Sze NSK; MacPherson REK; Tsiani E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396629
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress-mediated AMPK inactivation determines the high susceptibility of LKB1-mutant NSCLC cells to glucose starvation.
Ren Y; Chen J; Chen P; Hao Q; Cheong LK; Tang M; Hong LL; Hu XY; Celestial T Yap ; Bay BH; Ling ZQ; Shen HM
Free Radic Biol Med; 2021 Apr; 166():128-139. PubMed ID: 33636336
[TBL] [Abstract][Full Text] [Related]
6. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
7. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
[TBL] [Abstract][Full Text] [Related]
8. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC.
Cheng FJ; Chen CH; Tsai WC; Wang BW; Yu MC; Hsia TC; Wei YL; Hsiao YC; Hu DW; Ho CY; Li TS; Wu CY; Chou WY; Yu YL; Tang CH; Chen CY; Chen CM; Hsu JL; Chen HF; Chen Y; Tu CY; Hung MC; Huang WC
Oncogene; 2021 Feb; 40(6):1162-1175. PubMed ID: 33335306
[TBL] [Abstract][Full Text] [Related]
10. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
13. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective.
Ciccarese F; Zulato E; Indraccolo S
Oxid Med Cell Longev; 2019; 2019():8730816. PubMed ID: 31781355
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
[TBL] [Abstract][Full Text] [Related]
15. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas.
Brock SE; Rendon BE; Yaddanapudi K; Mitchell RA
J Biol Chem; 2012 Nov; 287(45):37917-25. PubMed ID: 22988252
[TBL] [Abstract][Full Text] [Related]
16. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of serine 399 in LKB1 protein short form by protein kinase Cζ is required for its nucleocytoplasmic transport and consequent AMP-activated protein kinase (AMPK) activation.
Zhu H; Moriasi CM; Zhang M; Zhao Y; Zou MH
J Biol Chem; 2013 Jun; 288(23):16495-16505. PubMed ID: 23612973
[TBL] [Abstract][Full Text] [Related]
18. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
19. Mir-451 inhibits proliferation and migration of non-small cell lung cancer cells via targeting LKB1/AMPK.
Liu Y; Li H; Li LH; Tang JB; Sheng YL
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):274-280. PubMed ID: 31389598
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells.
Mondal A; Roberge J; Gilleran J; Peng Y; Jia D; Akel M; Patel Y; Zoltowski H; Doraiswamy A; Langenfeld J
Cell Commun Signal; 2022 Jun; 20(1):99. PubMed ID: 35761398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
